Generic Name: sofosbuvir/velpatasvir/voxilaprevir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Multi-Class Combination Drugs

Company: Gilead Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: GS-7977 + GS-5816 + GS-9857

Drug Indication

This drug regimen was approved by the FDA to treat genotypes 1 through 6 in adults without cirrhosis or with compensated cirrhosis, and who have previously been treated with an HCV regimen containing an NS5A inhibitor, or have genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Vosevi has not yet been reviewed for inclusion in the AASLD/IDSA list of recommended HCV treatments.

General Info

  • Vosevi contains an approved nucleotide analog NS5B polymerase inhibitor (sofosbuvir) and NS5A inhibitor (velpatasvir), and an NS3 protease inhibitor (voxilaprevir). 

  • In clinical studies, approximately 96-97 percent of participants were cured with 12 weeks of therapy.
  • Vosevi was approved by the U.S. Food and Drug Administration for  treatment of chronic hepatitis C infection in adults for all genotypes on July 18, 2017.


Adult Dose: Vosevi combines thress drugs into a single tablet taken orally once daily with food for 12 weeks.

Pediatric Dose: N/A

Dosing Info: Treatment recommendations for Vosevi are determined by genotype and prior treatment experience.

Side Effects

The most common side effects are headache, fatigue, diarrhea and nausea.

Drug Interactions

  • For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vosevi or may require dose adjustments, consult the Vosevi package insert

Other Info

  • Warning: Patients who are coinfected with hepatitis B and C who take this medication may be at risk of hepatitis B virus (HBV) reactivation. Before taking this medication, be sure your doctor has tested you for evidence of current or prior hepatitis B virus infection.  HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in serious hepatitis flares, liver failure, and death. 
  • There are no adequate, well-controlled studies in pregnant women who have taken Vosevi. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • The safety of breast feeding while taking Vosevi has not been established.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: December 22, 2021